Abstract
Methadone maintenance therapy (MMT), a pharmacological treatment for opioid use disorder for the past 50 years, continues to remain controversial. Despite consistent and overwhelming evidence confirming the effectiveness and safety of MMT, misconceptions and myths persist regarding its legitimacy as a treatment for opioid addiction. This often results in the underutilization and limited availability of this treatment modality. Despite successful outcomes, the controversial nature of MMT, and the stigma experienced by the patients on methadone, has been a particularly difficult obstacle to overcome. We present the history of MMT, review the evidence for its efficacy in the treatment of opioid dependence, and explore the origins of the stigma and misconceptions related to MMT.
Similar content being viewed by others
References
Federal Narcotic Farm. Cal West Med, 1935. 42 (3): p. 228-9.
Administration, S.A.a.M.H.S. Federal guidelines for opioid treatment programs. Rockville: Substance Abuse and Mental Health Services Administration; 2015.
Control, U.S.D.o.J.O.o.D. Title 21 Code of Federal Regulations Part 1306: Prescriptions. 2015 [cited 2015 7/18/2015].
Courtwright DT. The prepared mind: Marie Nyswander, methadone maintenance, and the metabolic theory of addiction. Addiction. 1997;92(3):257–65.
Alcoholism, N.Y.O.o. and S.A. Services, methadone treatment works: a compendium for methadone maintenance treatment. 1994: New York State Office of Alcoholism and Substance Abuse Services.
Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA. 1965;193:646–50.
Stimmel B, Kreek MJ. Neurobiology of addictive behaviors and its relationship to methadone maintenance. Mt Sinai J Med. 2000;67(5-6):375–80.
Kaufman MJ et al. Cerebral phosphorus metabolite abnormalities in opiate-dependent polydrug abusers in methadone maintenance. Psychiatry Res. 1999;90(3):143–52.
Langleben DD et al. Acute effect of methadone maintenance dose on brain FMRI response to heroin-related cues. Am J Psychiatry. 2008;165(3):390–4.
Sees KL et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283(10):1303–10.
Nicholls L, Bragaw L, Ruetsch C. Opioid dependence treatment and guidelines. J Manag Care Pharm. 2010;16(1 Suppl B):S14–21.
Kreek MJ et al. Methadone use in patients with chronic renal disease. Drug Alcohol Depend. 1980;5(3):197–205.
Atkinson TJ, Fudin J., Wegrzyn EL, Bettinger JJ. Dialysis, opioids, and pain management: where’s the evidence? Practical Pain Management, 2014. 1-14.
Krambeer LL et al. Methadone therapy for opioid dependence. Am Fam Physician. 2001;63(12):2404–10.
Centers for Disease, C. and Prevention. Vital signs: risk for overdose from methadone used for pain relief—United States, 1999-2010. MMWR Morb Mortal Wkly Rep. 2012;61(26):493–7.
Chou R et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–30.
Medicine, t.A.A.o.P. The evidence against methadonea as a “Preferred” analgesic: a position statement from the American Academy of Pain Medicine. 2014. the American Academy of Pain Medicine.
Justo D et al. Methadone-associated Torsades de Pointes (polymorphic ventricular tachycardia) in opioid-dependent patients. Addiction. 2006;101(9):1333–8.
Katchman AN et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K (+) currents. J Pharmacol Exp Ther. 2002;303(2):688–94.
Bliesener N et al. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2005;90(1):203–6.
Hallinan R et al. Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. J Sex Med. 2008;5(3):684–92.
Kreek MJ. Rationale for maintenance pharmacotherapy of opiate dependence. Res Publ Assoc Res Nerv Ment Dis. 1992;70:205–30.
Gottheil E, Sterling RC, Weinstein SP. Diminished illicit drug use as a consequence of long-term methadone maintenance. J Addict Dis. 1993;12(4):45–57.
Gronbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand. 1990;82(3):223–7.
Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer Verlag; 1991.
Kleber HD. Methadone maintenance 4 decades later: thousands of lives saved but still controversial. JAMA. 2008;300(19):2303–5.
Novick DM et al. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch Intern Med. 1990;150(1):97–9.
Metzger DS et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993;6(9):1049–56.
Des Jarlais DC et al. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA. 1989;261(7):1008–12.
Novick DM et al. Methadone maintenance patients in general medical practice. A preliminary report. JAMA. 1988;259(22):3299–302.
Novick DM, Salsitz EA, Joseph H, Kreek MJ. Methadone medical maintenance: an early twenty-first century perspective. J Addict Dis. 2015;34(2-3):226–37.
Salsitz EA et al. Methadone medical maintenance (MMM): treating chronic opioid dependence in private medical practice—a summary report (1983-1998). Mt Sinai J Med. 2000;67(5-6):388–97.
Lawlor J. Many resist LePage administration’s bid to drop methadone as MaineCare benefit. Portland Press Herald: Portland, Maine; 2015.
Bukten A et al. Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study. Addiction. 2012;107(2):393–9.
Krupitsky E et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506–13.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Salsitz, E., Wiegand, T. Pharmacotherapy of Opioid Addiction: “Putting a Real Face on a False Demon”. J. Med. Toxicol. 12, 58–63 (2016). https://doi.org/10.1007/s13181-015-0517-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13181-015-0517-5